Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $59 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HRMY Hot Sheet
Price: $34.42 -7.02%
Rating Summary:
12 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
12 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Oppenheimer analyst Francois Brisebois raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $59.00 (from $56.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
- First Industrial Realty Trust (FR) PT Lowered to $62 at Truist Securities
- Harmony Biosciences posts Q3 revenue of $269M, reaffirms 2026 outlook
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
